Nath Bio-Genes (India) Ltd

NSE: NATHBIOGEN · BSE: 537291 · Food, Beverages & Tobacco · 17 announcements

Share price: ₹138.31
Market cap: ₹262.8 Cr
Revenue (annual): ₹445.1 Cr
Net profit (annual): ₹41.63 Cr
P/E (TTM): 7.2×Sector 28.6×
Promoter holding: 45.60%+0.00% QoQ
FII holding: 0.26%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

Announcement type

All Earnings Call 4 Other Announcement 3 Financial Results 3 Board Meeting Outcome 3 Annual General Meeting 2 ED Probe / Tax Survey 1 Board Meeting Date 1

Time

All time Last 1 week Last 1 month Last 2 months Last 3 months Last 6 months Last 1 year

3 announcements with these filters

4 May 2026 17:17 IST NSE

Board Meeting Outcome

Nath Bio-Genes (India) Board Meeting Outcome

Nath Bio-Genes (India) Limited announced board approval for the re-appointment of Mr. Hitesh Rajnikant Purohit as an Independent Director for a five-year term. Additionally, M/s. K.P. Sahasrabudhe and Co was appointed as the Internal Auditor for a 12-month tenure starting May 4, 2026.

Execution: 60 months (Director); 12 months (Auditor)

Read the filing ↗

25 Apr 2026 20:27 IST NSE

Board Meeting Outcome

Nath Bio-Genes (India) Board Meeting Outcome

Nath Bio-Genes (India) Limited has scheduled a board meeting on May 4, 2026, to consider audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The board will also consider recommending a final dividend for the financial year. The trading window remains closed until May 6, 2026.

Read the filing ↗

25 Apr 2026 20:26 IST BSE

Board Meeting Outcome

Nath Bio-Genes (India) Board Meeting Outcome

Nath Bio-Genes (India) Ltd will hold a Board Meeting on May 4, 2026. The board will consider audited financial results for Q4 and FY26, alongside a dividend recommendation for 2025-26. The trading window remains closed until May 6, 2026.

Read the filing ↗